SUBSCRIBE
SUBSCRIBE

Vistagen

NEWS
Illustration of hand holding trophy with people coming out of trophy and celebrating
Job Trends
BioSpace Announces 2025 Best Places to Work in Biopharma
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
November 12, 2024
 · 
6 min read
 · 
Angela Gabriel
Business
BioSpace Movers & Shakers. Dec. 4
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
December 3, 2020
 · 
7 min read
 · 
Alex Keown
Drug Development
VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
VistaGen’s oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.
November 13, 2018
 · 
1 min read
VistaGen Therapeutics.jpg
Business
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
Phase 3-ready asset expands VistaGen’s CNS pipeline and complements its neuropsychiatry focus on Major Depressive Disorder (MDD) with AV-101
September 22, 2018
 · 
9 min read
AWARDS
  • 2025 BPTW Badge - RBG.png
JOBS
IN THE PRESS
Press Releases
Vistagen to Present at the Stifel 2024 Healthcare Conference
November 14, 2024
 · 
1 min read
Press Releases
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
November 7, 2024
 · 
12 min read
Press Releases
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
November 5, 2024
 · 
6 min read
Press Releases
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
November 1, 2024
 · 
2 min read
Press Releases
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
October 9, 2024
 · 
5 min read
Press Releases
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
September 23, 2024
 · 
8 min read
Press Releases
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
July 9, 2024
 · 
6 min read
Biotech Bay
Vistagen to Present at the Jefferies Global Healthcare Conference
May 29, 2024
 · 
1 min read
Biotech Bay
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
May 23, 2024
 · 
6 min read
Biotech Bay
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
April 9, 2024
 · 
6 min read
Load More